Michael Crawford, MD
Interventional Cardiology · Ogden, UTNPI 1699760397
Payments from drug & device makers
What this record shows
This record is dominated by grants: $6,666 of the $7,514 with a category attached, or 88.7%. Medtronic accounts for 92.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $7,164 and has fallen 98.5% since, to $106 in 2025.
Across 23 payments — averaging $326.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Biosense Webster, Inc.$265
- Abbott$172
- Angiodynamics, Inc.$126
- Penumbra, Inc.$22
- Boston Scientific$19
What the payments were for
- Grants$6,66689%
- Food & beverage$5187%
- Education$3294%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 7 | $6,910 |
| Biosense Webster, Inc. | 10 | $265 |
| Abbott | 2 | $172 |
| Angiodynamics, Inc. | 2 | $126 |
| Penumbra, Inc. | 1 | $22 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUADRA ASSURA$157
- Carto 3$106
How this compares
$7,514 in reported general payments places this provider in the 55th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $83,090 |
| XareltoRivaroxaban | 26 | $25,155 |
| BrilintaTicagrelor | 38 | $17,911 |
| Metoprolol Succinate | 132 | $1,636 |
| Atorvastatin Calcium | 133 | $1,462 |
| ClopidogrelClopidogrel Bisulfate | 131 | $1,295 |
| Carvedilol | 89 | $890 |
| Isosorbide Dinitrate | 21 | $877 |
| Losartan Potassium | 68 | $630 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 84 | $504 |
| Lisinopril | 59 | $460 |
| Rosuvastatin Calcium | 18 | $423 |
| Ezetimibe | 20 | $404 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $388 |
| Potassium Chloride | 31 | $361 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Ogden
- Sanjeev TrehanOgden$95K
- Tareq HarbOgden$27K
- Sohail KhanOgden$4K
- Charlie BrunsonOgden$3K
- Yuri KhodakovOgden$1K
- Muhammad KhanOgden$1K
- Konstantyn SzwajkunOgden$65
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.